Prices of Sprycel and Fuzeon to be determined shortly

Published: 2008-03-05 06:58:00

Updated: 2008-03-05 06:58:00

Pharmaceutical sources say that attention has being focused on the prices of BMS's Sprycel (dasatinib), an oral inhibitor of multiple tyrosine kinases and Roche's anti-AIDS agent Fuzeon (enfuvirtide) to be determined at an insurance price coordination meeting slated for the second week of this mo...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK